Stock Market Reviews

HRMY (Harmony Biosciences Holdings, Inc.) News

Get the latest news, insights, and market updates on HRMY (Harmony Biosciences Holdings, Inc.). Explore the news page 6 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Harmony Biosciences (HRMY): Assessing Valuation After Recent Share Price Fluctuations
  Shares of Harmony Biosciences Holdings (HRMY) have seen mixed movement over the past month, with a recent decline following some earlier gains. Investors are watching closely to see how broader market conditions and internal financial trends play out. See our latest analysis for Harmony Biosciences Holdings. Zooming out, the recent 7-day share price return of 13.3% follows a much rockier long-term run for Harmony Biosciences Holdings. The 1-year total shareholder return is still down 28.6%...
  Oct 29, 2025 - $HRMY
• Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
  Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025 - $HRMY
• Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
  Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 28, 2025 - $HRMY
• Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last?
  Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Oct 24, 2025 - $HRMY
• Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
  PLYMOUTH MEETING, Pa., October 23, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following:
  Oct 23, 2025 - $HRMY
• Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
  Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 9, 2025 - $HRMY
• Harmony Biosciences (HRMY): Assessing Valuation After RECONNECT Trial Disappointment for ZYN002 in Fragile X Syndrome
  Harmony Biosciences Holdings (HRMY) is in the spotlight after announcing that its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its main goal, citing higher than expected placebo responses. This update is drawing fresh attention from investors and the biotech sector, given the drug’s prior promise in an area with limited treatment options. See our latest analysis for Harmony Biosciences Holdings. After the recent setback in the RECONNECT study, Harmony Biosciences...
  Oct 2, 2025 - $HRMY
• H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback
  Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the best low-priced growth stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their ‘Buy’ rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), while reducing the price target to $55 from $70, implying a potential upside of nearly 100%. The 21.43% downside in guidance follows the company’s Phase 3 […]
  Sep 29, 2025 - $HRMY
• Sector Update: Health Care Stocks Slide Thursday Afternoon
  Health care stocks declined Thursday afternoon, with the NYSE Health Care Index falling 1.8% and the
  Sep 25, 2025 - $HRMY
• HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
  Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
  Sep 25, 2025 - $HRMY